Dec 3 (Reuters) - Oxford Biomedica Plc:
* NOTES AN ANNOUNCEMENT BY NOVARTIS ON LONGER-TERM ANALYSES OF BOTH ELIANA AND JULIET PIVOTAL TRIALS
* OXFORD BIOMEDICA-KYMRIAH CONTINUED TO DEMONSTRATE STRONG EFFICACY WITH DURABLE RESPONSES AND MAINTAINED CONSISTENT AND WELL-CHARACTERISED SAFETY PROFILE Source text for Eikon: Further company coverage:
